These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 25616135)

  • 1. Estimating the cost-effectiveness of pre-exposure prophylaxis to reduce HIV-1 and HSV-2 incidence in HIV-serodiscordant couples in South Africa.
    Jewell BL; Cremin I; Pickles M; Celum C; Baeten JM; Delany-Moretlwe S; Hallett TB
    PLoS One; 2015; 10(1):e0115511. PubMed ID: 25616135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of pre-exposure prophylaxis targeted to high-risk serodiscordant couples as a bridge to sustained ART use in Kampala, Uganda.
    Ying R; Sharma M; Heffron R; Celum CL; Baeten JM; Katabira E; Bulya N; Barnabas RV
    J Int AIDS Soc; 2015; 18(4 Suppl 3):20013. PubMed ID: 26198348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa.
    Haberer JE; Baeten JM; Campbell J; Wangisi J; Katabira E; Ronald A; Tumwesigye E; Psaros C; Safren SA; Ware NC; Thomas KK; Donnell D; Krows M; Kidoguchi L; Celum C; Bangsberg DR
    PLoS Med; 2013; 10(9):e1001511. PubMed ID: 24058300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of HIV Pre-exposure Prophylaxis Among Heterosexual Men in South Africa: A Cost-Utility Modeling Analysis.
    Vogelzang M; Terris-Prestholt F; Vickerman P; Delany-Moretlwe S; Travill D; Quaife M
    J Acquir Immune Defic Syndr; 2020 Jun; 84(2):173-181. PubMed ID: 32141959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study.
    Hallett TB; Baeten JM; Heffron R; Barnabas R; de Bruyn G; Cremin Í; Delany S; Garnett GP; Gray G; Johnson L; McIntyre J; Rees H; Celum C
    PLoS Med; 2011 Nov; 8(11):e1001123. PubMed ID: 22110407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of tenofovir gel in urban South Africa: model projections of HIV impact and threshold product prices.
    Terris-Prestholt F; Foss AM; Cox AP; Heise L; Meyer-Rath G; Delany-Moretlwe S; Mertenskoetter T; Rees H; Vickerman P; Watts CH
    BMC Infect Dis; 2014 Jan; 14():14. PubMed ID: 24405719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modelling the impact and cost-effectiveness of combination prevention amongst HIV serodiscordant couples in Nigeria.
    Mitchell KM; Lépine A; Terris-Prestholt F; Torpey K; Khamofu H; Folayan MO; Musa J; Anenih J; Sagay AS; Alhassan E; Idoko J; Vickerman P
    AIDS; 2015 Sep; 29(15):2035-44. PubMed ID: 26355574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention.
    Mujugira A; Baeten JM; Donnell D; Ndase P; Mugo NR; Barnes L; Campbell JD; Wangisi J; Tappero JW; Bukusi E; Cohen CR; Katabira E; Ronald A; Tumwesigye E; Were E; Fife KH; Kiarie J; Farquhar C; John-Stewart G; Kidoguchi L; Panteleeff D; Krows M; Shah H; Revall J; Morrison S; Ondrejcek L; Ingram C; Coombs RW; Lingappa JR; Celum C;
    PLoS One; 2011; 6(10):e25828. PubMed ID: 21998703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiological impact and cost-effectiveness of providing long-acting pre-exposure prophylaxis to injectable contraceptive users for HIV prevention in South Africa: a modelling study.
    van Vliet MM; Hendrickson C; Nichols BE; Boucher CA; Peters RP; van de Vijver DA
    J Int AIDS Soc; 2019 Dec; 22(12):e25427. PubMed ID: 31855323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial.
    Celum C; Morrow RA; Donnell D; Hong T; Hendrix CW; Thomas KK; Fife KH; Nakku-Joloba E; Mujugira A; Baeten JM;
    Ann Intern Med; 2014 Jul; 161(1):11-9. PubMed ID: 24979446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated Delivery of Antiretroviral Treatment and Pre-exposure Prophylaxis to HIV-1-Serodiscordant Couples: A Prospective Implementation Study in Kenya and Uganda.
    Baeten JM; Heffron R; Kidoguchi L; Mugo NR; Katabira E; Bukusi EA; Asiimwe S; Haberer JE; Morton J; Ngure K; Bulya N; Odoyo J; Tindimwebwa E; Hendrix C; Marzinke MA; Ware NC; Wyatt MA; Morrison S; Haugen H; Mujugira A; Donnell D; Celum C;
    PLoS Med; 2016 Aug; 13(8):e1002099. PubMed ID: 27552090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What's love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis for HIV-serodiscordant couples.
    Ware NC; Wyatt MA; Haberer JE; Baeten JM; Kintu A; Psaros C; Safren S; Tumwesigye E; Celum CL; Bangsberg DR
    J Acquir Immune Defic Syndr; 2012 Apr; 59(5):463-8. PubMed ID: 22267018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial.
    Baeten JM; Donnell D; Mugo NR; Ndase P; Thomas KK; Campbell JD; Wangisi J; Tappero JW; Bukusi EA; Cohen CR; Katabira E; Ronald A; Tumwesigye E; Were E; Fife KH; Kiarie J; Farquhar C; John-Stewart G; Kidoguchi L; Coombs RW; Hendrix C; Marzinke MA; Frenkel L; Haberer JE; Bangsberg D; Celum C;
    Lancet Infect Dis; 2014 Nov; 14(11):1055-1064. PubMed ID: 25300863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-serodiscordant couples desiring a child: 'treatment as prevention,' preexposure prophylaxis, or medically assisted procreation?
    Mabileau G; Schwarzinger M; Flores J; Patrat C; Luton D; Epelboin S; Mandelbrot L; Matheron S; Yazdanpanah Y
    Am J Obstet Gynecol; 2015 Sep; 213(3):341.e1-12. PubMed ID: 25979615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of Pre-exposure HIV Prophylaxis During Pregnancy and Breastfeeding in Sub-Saharan Africa.
    Price JT; Wheeler SB; Stranix-Chibanda L; Hosek SG; Watts DH; Siberry GK; Spiegel HM; Stringer JS; Chi BH
    J Acquir Immune Defic Syndr; 2016 Aug; 72 Suppl 2(Suppl 2):S145-53. PubMed ID: 27355502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial.
    Mugo NR; Hong T; Celum C; Donnell D; Bukusi EA; John-Stewart G; Wangisi J; Were E; Heffron R; Matthews LT; Morrison S; Ngure K; Baeten JM;
    JAMA; 2014 Jul 23-30; 312(4):362-71. PubMed ID: 25038355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of easy-access, risk-informed oral pre-exposure prophylaxis in HIV epidemics in sub-Saharan Africa: a modelling study.
    Phillips AN; Bershteyn A; Revill P; Bansi-Matharu L; Kripke K; Boily MC; Martin-Hughes R; Johnson LF; Mukandavire Z; Jamieson L; Meyer-Rath G; Hallett TB; Ten Brink D; Kelly SL; Nichols BE; Bendavid E; Mudimu E; Taramusi I; Smith J; Dalal S; Baggaley R; Crowley S; Terris-Prestholt F; Godfrey-Faussett P; Mukui I; Jahn A; Case KK; Havlir D; Petersen M; Kamya M; Koss CA; Balzer LB; Apollo T; Chidarikire T; Mellors JW; Parikh UM; Godfrey C; Cambiano V;
    Lancet HIV; 2022 May; 9(5):e353-e362. PubMed ID: 35489378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modelling impact and cost-effectiveness of oral pre-exposure prophylaxis in 13 low-resource countries.
    Pretorius C; Schnure M; Dent J; Glaubius R; Mahiane G; Hamilton M; Reidy M; Matse S; Njeuhmeli E; Castor D; Kripke K
    J Int AIDS Soc; 2020 Feb; 23(2):e25451. PubMed ID: 32112512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost-effectiveness of multi-purpose HIV and pregnancy prevention technologies in South Africa.
    Quaife M; Terris-Prestholt F; Eakle R; Cabrera Escobar MA; Kilbourne-Brook M; Mvundura M; Meyer-Rath G; Delany-Moretlwe S; Vickerman P
    J Int AIDS Soc; 2018 Mar; 21(3):. PubMed ID: 29537654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modelling the Epidemiological Impact and Cost-Effectiveness of PrEP for HIV Transmission in MSM in China.
    Zhang L; Peng P; Wu Y; Ma X; Soe NN; Huang X; Wu H; Markowitz M; Meyers K
    AIDS Behav; 2019 Feb; 23(2):523-533. PubMed ID: 29971734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.